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Hepatitis B (HB) is one of the most common and serious infectious diseases, and about 5% of the population of the world are chronic carriers of HB virus. Nearly 25% 
of all carriers develop serious liver diseases such as chronic 
hepatitis, cirrhosis, and primary hepatocellular carcinoma [1]. In 
endemic areas of Africa and Asia, the epidemiological patterns 
differ from those seen in North America and Western Europe. 
In these regions, most infections occur in infants and children 
as a result of maternal-neonatal transmission or close childhood 
contact; although percutaneous exposure with contaminated 
needles or following unsafe injections is always a possibility in 
these countries [1]. With a prevalence of 2-7% HB surface antigen 
(HBsAg) seropositivity, India has an intermediate endemicity, 
and a projected burden of 50 million carriers, the 2nd largest in the 
world [2,3]. In India, the HBsAg prevalence rate among pregnant 
women varies between 0.9% and 11.2% [4-6]. Without immune 
prophylaxis, in mothers who are both HBsAg and Hepatitis B e 
antigen (HBeAg) positive, the risk for transmission to the baby is 
between 70% and 90% by 6 months of age, whereas in the case 
of mothers who are HBsAg positive, but HBsAg negative, it is 
<10% [7-10].
Perinatal exposure is the most common mode of 
transmission in neonates. More than 90% of infected infants 
become chronic carriers. Prevention of perinatal transmission 
of HB is important to decrease overall carrier state. The 
transmission of perinatal HB infection can be prevented in 
70-95% of neonates born to HBsAg positive mothers by early 
active immunization and 85-95% by combined active and 
passive immunoprophylaxis.
Although the introduction of the birth dose of HB vaccine 
(HBV) will go a long way to reduce maternal-neonatal 
transmission, there needs to be a system in place to ensure 
universal screening during pregnancy, timely administration of 
the birth dose and tracking of babies exposed to HB. Awareness 
of the current recommendations for managing babies of mothers 
who are HB carriers is not universal, resulting in failure of 
follow-up, despite the serious long-term implications including 
development of hepatocellular carcinoma [11]. In this context, 
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this study attempts to estimate the rate of HB carrier status 
among infants born to positive mothers at 10 months of age 
by measuring serum HBsAg levels and to assess the efficacy 
of prophylaxis as measured by the anti-HBs antibody titers at 
10 months of age.
METHODOLOGY
We recruited HBsAg positive mothers from the labor room 
and postnatal ward of SAT Hospital, Trivandrum, which is a 
tertiary care teaching hospital between 1st April and October 
31st 2008 and had a prospective follow-up of the infants at 
6 weeks, 14 weeks, and 10 months of age. All consecutive, 
live born neonates, born to HBsAg positive mothers were 
included in the study. Parents of neonates, recruited for the 
study, were counseled about the disease, need for post-exposure 
prophylaxis and follow-up. After obtaining informed consent 
from the parents, 0.5 ml of recombinant vaccine (Revac-b 
from Bharat Biotech-Hyderabad) was given intramuscularly 
into the right thigh within 12 h of birth from the hospital free 
of cost. HB immunoglobulin (HBIG) was given to only those 
who could afford to buy it. Hepatitis 100 IU (0.5 ml) from 
VHB Pharmaceuticals was given intramuscularly into the left 
thigh within 24 h of birth. Half-life of HBIG is 23.1±5.5 days. 
At 6 and 14 weeks of age, 0.5 ml of recombinant vaccine was 
given according to the IAP immunization schedule along with 
other UIP vaccines to all neonates. Three dose schedules were 
the protocol followed in our hospital.
At 10 months of age (or plus 1 week), informed consent 
for blood sample collection was obtained from the parents 
of the children. Blood samples were drawn after taking 
universal precautions. The sera were separated and stored at 
20°C until tested. HyperCard “Sand which” immune assay kit 
(J Mitra and Co., Ltd., New Delhi) was used for HBsAg status 
determination and electro chemiluminescent immunoassay 
using ELECSYS 2010 system (Roche diagnostics GmbH, 
Mannheim, Germany) for the estimation of anti-HBs antibody 
titer. All tests were conducted in advanced clinical and 
research lab attached to the Medical College, Trivandrum. 
Infants with anti-HBs titer >100 IU/L were considered as good 
responders. If anti-HBs titer was <10 IU/L (nonresponder), 
the whole vaccine series was repeated by 0, 1, 6 schedule and 
post-vaccination serology was done after 2 months. If the 
anti-HBs titer was 10 to 100 IU/L (poor responder), 1 booster 
dose of HBV was given. Post-vaccination serology was done 
after 2 months. The study protocol was approved by the 
Institutional Ethics Committee.
Demographic details and follow-up information along with 
estimates of biochemical markers were collected in a case 
record format for each HBsAg positive mother-infant pair. Data 
entered into the Microsoft Excel 2003 and analyzed by SPSS 
11.0 windows at clinical epidemiology research training center, 
medical college, Trivandrum. Independent sample t-test was used 
to compare continuous variables and Chi-square was used to 
compare discrete variables. For the comparison of anti-HBs titer 
in the vaccine alone group and vaccine plus HBIG combination 
group was done by Mann–Whitney test. Geometric mean titer 
was also calculated.
RESULTS
The total number of deliveries during the study period was 
8365. There were 125 mothers who were HBsAg positive. 
This gives an estimated prevalence rate of HBsAg positivity 
in pregnant women at birth as 1.5%. Mean maternal age was 
24.1±2.28 years. 60.8% of the mothers were primigravida and 
16 (12.8%) mothers had a history of the previous abortions. 
99/125 (79.2%) had vaginal deliveries. In 3 cases, husbands 
were HB carriers and none of them had given a history of 
transfusion of blood products. None of them had evidence of 
other reproductive tract infections. In 32 cases, HBsAg titer was 
measured; of which, 8 (25%) were HBsAg positive. Due to very 
small number, separate analysis of that subgroup was not done. 
Majority (119 [95.2%]) of them were term babies and 6 (4.8%) 
were preterm. Mean birth weight was 2.88±0.41 kg and all 
were exclusively breastfed till 6 months of age. The baseline 
characteristics are summarized in Table 1.
All 125 children were vaccinated with HBV within 12 h while 
HBIG was given to 96 infants (76.8%). Only 69 (55.2%) of the 
cohort completed 3rd visit as ours is a referral hospital where 
HBsAg positive mothers are being referred for the delivery. 
They go back to nearby hospital for vaccinations. Carrier state 
in infants born to HB positive mothers at 10 months based on 
HBsAg positivity was 1/69 (1.44%). 43/69 (62.35%) had good 
antibody response, and among them, 41 received HBV plus 
HBIG combination. Among 7 infants who received vaccine 
alone, 2 had good antibody response (p=0.02). Mean antibody 
titer in vaccine group (163.38) was significantly different from 
that of the combined group (443.14), (p=0.011). We compared 
geometric means also and in combined group, it was 164.02 while 
it was 9.75 in the vaccine group (p=0.01). The comparisons of 
risk are summarized in Tables 2 and 3.
Table 1: Baseline characteristics of HBV alone and HBV+HBIG 
combination groups
Variables HBIG+HBV 
vaccine  
(n=96)
HBV vaccine 
alone  
(n=29)
Significance 
(p-value)
Male to female ratio 52:44 15:14 0.57
Urban:Rural 15:81 4:25 0.810
Mean maternal 
age (SD)
24.08 (2.31) 24.17 (2.25) 0.85
Primigravida: Others 62:34 14:15 0.118
Husband carrier 2 1
Normal: Others 75:21 24:5 0.636
Mean baby weight 2.93 (0.409) 2.72 (0.372) 0.01
Term: Preterm 92:4 27:2 0.548
HBV: Hepatitis b vaccine, HBIG: Hepatitis b immunoglobulin, SD: Standard 
deviation
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DISCUSSION
This study has highlighted the need for implementing an effective 
policy for the management and follow-up of neonates born to 
HBsAg positive mothers. It is reported that without prophylaxis, 
40% of the infants born to HBsAg positive mothers will get 
infected [12]. In our study in which 69 out of 125 HBsAg positive 
mothers were followed up, 1 infant was HBsAg positive at 
10 months which comes to an incidence of 1.5%. It is reported 
that despite newborn immunoprophylaxis, vertical transmission 
may still occur in 1-14% cases [13]. Thus, the incidence seen in 
our setting is at par with the reported literature. However, it is 
important to note that at the time of the study the use of HBIG 
was not available free of cost for the patients in the tertiary care 
setting itself and hence, some of the families could not afford it. 
Non-compliance to the follow-up visit could be attributed to ease 
of accessibility to immunization services in all areas in the state 
and availability of child health specialist everywhere. Families 
preferred to have postnatal visits at their residential areas.
The combination of HBV with HBIG has provided significant 
protective efficacy compared to the HBV alone group (relative 
risk=3.05). In 65.4% of the infants who had an adequate response, 
it could be attributed to the intervention alone. It is already 
established that the combined vaccine and immunoglobulin given 
at birth reduces the risk of transmission significantly. However, 
it is important to note that nearly 23% of those infants who 
received a combination of HBV and HBIG were found to be poor 
responders at 10 months necessitating additional booster dose. 
This highlights the need for proper follow-up and documentation 
of the cases. There is also the need to establish laboratory 
capacity for estimation of biomarkers free of cost. This study does 
have limitations with nearly 45% not completing the adequate 
follow-up. Furthermore, the loss to follow-up was significantly 
more in the vaccine alone group, and it is not possible to predict 
how this would have influenced the risk estimate.
CONCLUSION
Our study demonstrated an adequate response in infants provided 
with combination prophylaxis compared to vaccine alone and 
highlighted the possibility of poor responders. The possibility of 
poor response makes it imperative that the follow-up needs to be 
meticulous along with adequate awareness building for parents 
on the need for follow-up. Figure 1 shows the summary of the 
subjects followed up.
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